Yeast two-hybrid system is called as Y2H or two-hybrid screening, is a molecular biology method used to discover the interaction of protein-protein and protein-DNA. Yeast two-hybrid system is a specific and cost-effective genetic technique used in the testing of interaction between the targeted proteins, or screening the libraries of proteins fragments made from the desired cell types, tissues or entire organisms. This yeast two-hybrid system technique is commonly used in research and development activities to discover protein interactions. The global Yeast two-hybrid system is likely to expand due to the advancement in the healthcare industry and rising demand for cost-effective protein test.
Pandemic coronavirus is believed to have a severe impact on the global yeast two-hybrid system market. Yeast two-hybrid system market manufacturing industries are being shuttered around the world causing an unusual technology and business model transformation. The outbreak of coronavirus has brought on many aspects, like falling business assurance, uncertainty about future, massive slowing of the supply chain, and others. As coronavirus has become the main focus, all, biotech companies, pharmaceutical companies, and research institutes are appointed in collaboration work to deal with Covid-19. This led to the shifting of their focus and also all the resources in making coronavirus vaccines. This is hampering the yeast two-hybrid system market.
The major driver of the global yeast two-hybrid system market growth is the rising demand of screening method to discover the protein interaction and introduction of sensitive and cost-effective test. Also, the rapid advancement in molecular biology is likely to drive the yeast two-hybrid system market growth. Other factors such as the assistance of yeast under restrictive conditions and growing acceptance of yeast two-hybrid by research community are also likely to drive the global yeast two-hybrid system market growth. However, the stringent regulations imposed by the authorities on the research and development activities and limited investment in developing countries can restrain the growth of the global yeast two-hybrid system market.
The global yeast two-hybrid system market has been segmented on the basis of technique, application, and end-user.
Based on the technique, the global yeast two-hybrid system market can be segmented as:
Based on the application, the global yeast two-hybrid system market can be segmented as:
Based on the end-user, the global yeast two-hybrid system market can be segmented as:
Based on the technique, the protein-protein interaction segment is expected to hold a major share in the global yeast two-hybrid system market. Based on the application, the therapeutic segment is expected to be the most dominating segment in the global yeast two-hybrid system market. Based on the end-user, the pharmaceutical and biotechnology companies segment is expected to dominate the global yeast-two hybrid system market due to higher number of research and development activities.
The global yeast two-hybrid system market is expected to be dominated by North America, due to the technological advancement and higher research and development activities in the region. Also, advancement in molecular biology is likely to drive the yeast two-hybrid system market in the region. Europe is expected to be the next dominant region, due to the growing pharmaceutical and biotechnology companies in the region. Asia-Pacific is expected to show a rapid growth in the global yeast two-hybrid system market over the forecast period due to the increasing demand for cost-effective test and rising government investment in the research and development activities. Also, advancement in the healthcare industry in countries like India and China is expected to drive the market growth.
There are some of the market leaders in the global yeast two-hybrid system market identified across the value chain: Takara Co., Ltd., Thermo Fisher Scientific, Agilent Technologies, Inc., Creative Biolabs, Inc., Jubilant Life Sciences, Charles River Laboratories, Inc., Eurofins, Sarcomics Biostructures, Genscript Biotech, Profacgen, and others.
The report covers exhaustive analysis on:
Regional analysis includes